Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Hsp90 molecular chaperone inhibitors: are we there yet?
L Neckers, P Workman - Clinical cancer research, 2012 - aacrjournals.org
Heat shock protein (Hsp) 90 is an ATP-dependent molecular chaperone that is exploited by
malignant cells to support activated oncoproteins, including many cancer-associated …
malignant cells to support activated oncoproteins, including many cancer-associated …
HSP90 and the chaperoning of cancer
L Whitesell, SL Lindquist - Nature Reviews Cancer, 2005 - nature.com
Standing watch over the proteome, molecular chaperones are an ancient and evolutionarily
conserved class of proteins that guide the normal folding, intracellular disposition and …
conserved class of proteins that guide the normal folding, intracellular disposition and …
[HTML][HTML] Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display
variable sensitivity to therapeutics and may play different roles in progression. We previously …
variable sensitivity to therapeutics and may play different roles in progression. We previously …
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
A Kamal, L Thao, J Sensintaffar, L Zhang, MF Boehm… - Nature, 2003 - nature.com
Abstract Heat shock protein 90 (Hsp90) is a molecular chaperone that plays a key role in the
conformational maturation of oncogenic signalling proteins, including HER-2/ErbB2, Akt, Raf …
conformational maturation of oncogenic signalling proteins, including HER-2/ErbB2, Akt, Raf …
Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/p21WAF1/CIP1 and p27KIP1 pathway
Resveratrol (RES) is the most effective natural products used for the treatment of a variety of
cancers. In this study, we tested the effect of RES in enhancing the efficacy of docetaxel …
cancers. In this study, we tested the effect of RES in enhancing the efficacy of docetaxel …
Targeting the cell cycle: a new approach to cancer therapy
GK Schwartz, MA Shah - Journal of clinical oncology, 2005 - ascopubs.org
The cell cycle represents a series of tightly integrated events that allow the cell to grow and
proliferate. Critical parts of the cell cycle machinery are the cyclin-dependent kinases …
proliferate. Critical parts of the cell cycle machinery are the cyclin-dependent kinases …
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer …
Purpose: HSP90 is a chaperone protein required for the stability of a variety of client
proteins. 17-Demethoxygeldanamycin (17-AAG) is a natural product that binds to HSP90 …
proteins. 17-Demethoxygeldanamycin (17-AAG) is a natural product that binds to HSP90 …
Hsp90 inhibitors as novel cancer chemotherapeutic agents
L Neckers - Trends in molecular medicine, 2002 - cell.com
Abstract Heat shock protein 90 (Hsp90) is a molecular chaperone whose association is
required for the stability and function of multiple mutated, chimeric and over-expressed …
required for the stability and function of multiple mutated, chimeric and over-expressed …
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis
SA Eccles, A Massey, FI Raynaud, SY Sharp… - Cancer …, 2008 - aacrjournals.org
We describe the biological properties of NVP-AUY922, a novel resorcinylic isoxazole amide
heat shock protein 90 (HSP90) inhibitor. NVP-AUY922 potently inhibits HSP90 (K d= 1.7 …
heat shock protein 90 (HSP90) inhibitor. NVP-AUY922 potently inhibits HSP90 (K d= 1.7 …
Heat shock protein 90 as a molecular target for cancer therapeutics
JS Isaacs, W Xu, L Neckers - Cancer cell, 2003 - cell.com
Cancer is a disease characterized by genetic instability. Although identification of novel
therapeutic agents via molecular targeting offers the promise of great specificity coupled with …
therapeutic agents via molecular targeting offers the promise of great specificity coupled with …